Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease

Eriksson, Anders; Häggström, Jens; Pedersen, Henrik D.; Hansson, Kerstin; Järvinen, Anna‐Kaisa; Haukka, Jari; Kvart, Clarence

doi:10.1016/j.jvc.2014.05.001

Cited by 12 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Having a higher heart rate was associated with an increased hazard of presumed stage B dogs progressing to initiation of potent diuretic treatment or cardiac‐related death. This finding concurs with previous studies that observed associations between increased heart rate and adverse cardiac outcome in dogs with preclinical DMVD . Moreover, studies evaluating the prognostic value of heart rate in dogs with a wider range of DMVD severity (including those diagnosed with CHF) reported that having a higher heart rate was associated with an increased hazard of adverse outcome.…”

Section: Discussionsupporting

confidence: 92%

“…This observation concurs with the findings of a randomized controlled trial that observed an association between higher heart murmur intensity and shorter time until developing CHF in CKCSs with preclinical DMVD . In agreement, another study reported that CKCSs with heart murmur intensities ≥III/VI had an increased hazard of developing CHF than did those with lower intensity murmurs . Moreover, heart murmur intensity has been found to correlate with DMVD disease severity and was associated with cardiac‐related death in another cohort of dogs with DMVD attending a UK research clinic .…”

Section: Discussionsupporting

confidence: 88%

“…Previous observational studies and randomized controlled trials have evaluated factors associated with disease progression in dogs with stage B DMVD . Natriuretic peptides, radiographic and echocardiographic measurements, presenting signs and physical examination findings, age, systolic arterial blood pressure, and pimobendan treatment have been reported to be associated with outcome in dogs with preclinical DMVD. However, the samples of dogs included in these studies were restricted to those attending teaching or referral hospitals or a single breed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom

Mattin

Brodbelt

Church

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Factors associated with disease progression in dogs with preclinical (stage B) degenerative mitral valve disease (DMVD) have not been evaluated previously in primary care veterinary practice. Objectives To evaluate whether plasma cardiac biomarkers, clinical signs, and physical examination findings are associated with clinical progression (reaching the composite endpoint of initiation of treatment with a potent diuretic or cardiac death) in dogs presumed to have stage B DMVD. Animals Six‐hundred and eighty‐four dogs diagnosed with DMVD recruited from 73 primary care practices in the United Kingdom. Dogs were not receiving potent diuretics at recruitment. Methods Prospective cohort study design. Primary care veterinarians recorded the presence or absence of clinical signs and physical examination findings. Baseline plasma N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and cardiac troponin I were measured. Cox regression models measured associations between risk factor variables and clinical progression. Flexible parametric models generated predicted probabilities of reaching the composite endpoint for dogs with different combinations of prognostic risk factor variables. Results Plasma NT‐proBNP, heart rate, heart murmur intensity, presence of a cough, being a Cavalier King Charles Spaniel, and being prescribed pimobendan were associated with clinical progression to initiation of treatment with a potent diuretic or cardiac‐related death. Conclusions and Clinical Importance Dogs with stage B DMVD identified as having a high risk of disease progression might benefit from more frequent monitoring or further diagnostic evaluation. The prognostic factors identified could facilitate risk stratification of dogs presenting with preclinical DMVD.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom

Mattin

Brodbelt

Church

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Elevated concentrations of NT-proBNP (> 800 pmol/L), cTnI (> 0.03 ng/mL), and CK-MB (> 6.3 U/L) were documented in all animals enrolled in the study, but increased NT-proANP (> 1,000 pmol/L) was found in only 66.6% (12/18) of the dogs. However, when all subjects were considered together, the mean values of all four cardiac specific biomarkers were above the reference range for normal dogs (Montes et al 1987, Sleeper et al 2001, Ettinger and Prosek 2010, Eriksson et al 2014.…”

Section: Statistical Analysesmentioning

confidence: 96%

Cardiac biomarkers in dogs with visceral leishmaniasis

et al. 2016

View full text Add to dashboard Cite

ABSTRACT.Although only a few studies have focused on the cardiac alterations in Leishmania spp. infected dogs, myocardial inflammation ascribed to such parasite has been documented in some animals. In spite of the increasing popularity of cardiac biomarkers in veterinary medicine in recent years, it remains unknown how most of these substances would perform in dogs with visceral leishmaniasis. In this study, we hypothesised that Leishmania spp. would damage cardiac myofibers resulting in increased circulating levels of cardiac specific markers in dogs. Therefore, biomarkers of myocyte injury and stress were investigated in 18 dogs with naturally-occurring visceral leishmaniasis presenting varying clinical signs, including completely asymptomatic animals. The median (min-max) concentrations of NT-proANP, NT-proBNP, cTnI, and CK-MB were 1138.0 (875-1175) pmol/L, 1160.0 (803-2034) fmol/L, 0.22 (0.15-0.51) ng/mL, and 116.7 (113-222) U/L, respectively. No differences were documented for the concentration of the natriuretic peptides and CK-MB in accordance with the severity of clinical signs, but for cTnI a significant difference was reported when comparing asymptomatic and symptomatic animals. Also, the compromise of renal tubular function seemed to interfere with the concentration of the natriuretic peptides and cTnI. In conclusion, all cardiac-specific biomarkers were elevated when compared to the normal range previously proposed for dogs. Measuring specific cardiac biomarkers has the potential to non-invasively document myocardial injuries attributable to visceral leishmaniasis.Key words: parasitic disease, myocarditis, natriuretic peptides, troponins. RESUMEN.A pesar de que solo unos pocos estudios se han centrado en las alteraciones cardíacas en perros infectados por la Leishmania spp., la inflamación miocárdica atribuida a este parásito ha sido documentada en algunos animales. Los marcadores cardiacos en medicina veterinaria han experimentado una creciente popularidad en los últimos años, sin embargo aún no se sabe cómo la mayoría de estas substancias se comporta en perros con leishmaniasis visceral. En este estudio, se presume que Leishmania spp. dañaría fibras cardiacas causando un aumento de los niveles circulantes de marcadores cardiacos en perros. Biomarcadores de lesión y de estrés de los miocitos fueron investigados en 18 perros con infección natural por Leishmania spp. y que presentaban diversos signos clínicos, incluyendo los animales totalmente asintomáticos. La mediana (mín-máx) de las concentraciones de NT-proANP, NT-proBNP, cTnI, CK-MB fueron 1138,0 (875-1175) pmol/L, 1160,0 (803-2034) fmol/L, 0,22 (0,15 -0,51) ng/mL y 116,7 (113-222) U/L, respectivamente. No se registraron diferencias para la concentración de los péptidos natriuréticos y CK-MB de conformidad con la gravedad de los síntomas clínicos, pero para la cTnI se observó diferencia significativa al comparar los animales sintomáticos y asintomáticos. Además, el compromiso de función tubular renal parece interferir con la concentración de los...

show abstract

“…Genotyping of the selected SNPs and quantification of systemic levels of MMP-2 and MMP-9 were assessed for evaluating associations between the genotypes and MVD risk and with the clinical disease phenotypes (i.e., circulating amount of two enzymes, severity, and complications). For this last objective, systemic levels of pro-atrial natriuretic peptide (pro-ANP) were also quantified due to the emerging evidence suggesting a significant association between high circulating pro-ANP levels and severity and complication of degenerative MVDs [19][20][21][22]. These investigations might permit to evidence whether the genetic variants selected and the circulating blood levels of their molecules and the pro-ANP may be potential predictive, diagnostic, and prognostic biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Associations of rs3918242 and rs2285053 MMP-9 and MMP-2 polymorphisms with the risk, severity, and short- and long-term complications of degenerative mitral valve diseases: a 4.8-year prospective cohort study

Balistreri

Allegra

Crapanzano

et al. 2016

Cardiovascular Pathology

View full text Add to dashboard Cite

Keywords:Degenerative forms of mitral valve diseases Metalloproteinases rs3918242, rs243865, rs2285053 MMP-2 and MMP-9 gene SNPs Management and outcome Background: Degenerative forms of mitral valve diseases (MVDs) are very complex pathologies. Thus, it is difficult to make generalizations about the disease pathways or genetic risk factors contributing to these diseases. However, a key role of metalloproteinases (MMPs) in their pathophysiology is emerging. Thus, we performed for the first time a perspective study to assess eventual associations of some functional single nucleotide polymorphisms (SNPs) in MMP-2 and MMP-9 genes with the MVD risk, symptom severity, and short-and long-term (4.8 years) complications. Materials and methods: For this purpose, 90 patients and two control groups were genotyped for rs3918242, rs243865, and rs2285053 MMP-2 and MMP-9 gene SNPs, and systemic levels of pro-atrial natriuretic peptide (pro-ANP) and two enzymes were quantified and correlated to genotypes of MMP-2 and MMP-9 SNPs studied. In addition, associations between these SNPs and symptom severity and short-and long-term (4.8 years) complications were evaluated. Results: Interestingly, rs3918242 MMP-9 and rs2285053 MMP-2 SNPs were significantly represented in cases than two control groups and were associated with a higher MVD risk, as demonstrated using dominant/recessive models. Cases stratified for NYHA symptoms and particularly those NYHA III+IV with rs3918242 CT+TT MMP-9 and rs2285053CT+TT genotypes also showed higher severity related to significant higher systemic levels of MMP enzymes and pro-ANP at enrolment and 4.8 follow-up times. In addition, cases with these genotypes and particularly those NYHA III+IV had a very significant percentage of complications, particularly at the 4.8 follow-up. Surprisingly, 20% of patient controls developed MVD at 4.8-year follow-up and were carriers of these genotypes. Conclusion: Thus, the associations observed seem to suggest that the two SNPs might represent useful biomarkers and targets for preventing and monitoring MVDs and developing personalized treatments, consenting a more appropriate management and outcome.

show abstract

Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease

Cited by 12 publications

References 49 publications

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom

Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom

Cardiac biomarkers in dogs with visceral leishmaniasis

Associations of rs3918242 and rs2285053 MMP-9 and MMP-2 polymorphisms with the risk, severity, and short- and long-term complications of degenerative mitral valve diseases: a 4.8-year prospective cohort study

Contact Info

Product

Resources

About